Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes. (TUMOSPEC)
Hereditary Breast and Ovarian Cancer, Mutation
About this trial
This is an interventional prevention trial for Hereditary Breast and Ovarian Cancer focused on measuring Oncogeneticists, Mutations, Breast Cancer, Ovarian cancer
Eligibility Criteria
Inclusion criteria:
Index case eligibility:
Any person with an indication for a BRCA1/BRCA2 gene analysis and who has been offered TUMOSPEC panel screening.
Age ≥18 years.
Family member eligibility:
Family members will be eligible if the mutation identified in the Index Case is considered deleterious.
Any family member to the first and second decree or a cousin of the Index Case. Family members from both sides of the family will be invited to take part.
Age ≥18 years.
Exclusion Criteria:
People deprived of their civil liberties or who are under judicial protection or guardianship.
Patients unable to answer the questionnaire for social or psychological reasons.
Children of the index cases, of any age.
Sites / Locations
- Gustave Roussy
- Institut Curie - PIGERecruiting
Arms of the Study
Arm 1
Other
Analysis of the gene panel
The laboratory will carry out the TUMOSPEC gene panel analysis at the same time as the BRCA1 and BRCA2 analysis and will return a negative (no mutation) or positive (presence of a mutation allowing enrolment of family members) result.